Capricor, Inc.

7 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

May 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Feb 6, 2027
The maintenance fee for Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy (US 10,369,173) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
1 fee due Mar 19, 2027
The maintenance fee for Methods and Compositions for Treating Skeletal Muscular Dystrophy (US 11,759,482) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
1 fee due Apr 30, 2027
The maintenance fee for Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles (US 11,801,268) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Patent	Title	Status	Expires	Confidence
US 10,369,173	Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy In force Ends no later than May 31, 2033 · From the USPTO record	In force	Ends no later than May 31, 2033	From the USPTO record
US 9,884,076	Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy In force Term ends Aug 19, 2033 · From the USPTO record	In force	Term ends Aug 19, 2033	From the USPTO record
US 10,695,293	Method of preventing or treating radiation-induced dermatitis with extracellular vesicles In force Term ends Mar 17, 2037 · From the USPTO record	In force	Term ends Mar 17, 2037	From the USPTO record
US 11,801,268	Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles In force Term ends Sep 18, 2037 · From the USPTO record	In force	Term ends Sep 18, 2037	From the USPTO record
US 11,529,376	Methods of treating systemic graft-versus-host disease with extracellular vesicles In force Term ends Oct 4, 2038 · From the USPTO record	In force	Term ends Oct 4, 2038	From the USPTO record
US 11,759,482	Methods and Compositions for Treating Skeletal Muscular Dystrophy In force Term ends Mar 3, 2040 · High confidence	In force	Term ends Mar 3, 2040	High confidence
US 12,433,941	Exosomal Nucleic Acid Vaccine Modularly Configured to Harness Multiple Antigen Presentation Mechanisms In force Term ends Oct 10, 2042 · High confidence	In force	Term ends Oct 10, 2042	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

11 pending · 2 abandoned · 4 no status recorded

List them